The OCEANIC-AF trial compared the novel factor XIa inhibitor, asundexian, to apixaban in patients with atrial fibrillation. Despite lower bleeding risk, asundexian did not prevent stroke or systemic embolism as effectively as apixaban. The trial was halted due to lack of efficacy for asundexian. The results showed that asundexian was associated with a higher risk of stroke, systemic embolism, and ischemic stroke compared to apixaban. More research is needed to determine the appropriate level of factor XI inhibition for stroke prevention in patients with atrial fibrillation. These findings highlight the importance of optimal dosing and patient response to different therapies.
Source link
Asundexian did not prevent stroke, systemic embolism vs. apixaban in atrial fibrillation
